Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

The Journal.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. 


Further Listening:

Trillion Dollar Shot 

Why WeightWatchers Wants in on Drugs Like Ozempic  


Sign up for WSJ’s free What’s News newsletter.


Learn more about your ad choices. Visit megaphone.fm/adchoices

More description

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. 


Further Listening:

Trillion Dollar Shot 

Why WeightWatchers Wants in on Drugs Like Ozempic  


Sign up for WSJ’s free What’s News newsletter.


Learn more about your ad choices. Visit megaphone.fm/adchoices

2025-05-21 19 min
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in

Chapters

No chapters available.